Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
642,643

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2

CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.

    LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up

    LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.

      Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

      The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

        Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised

        Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.

          Should You Buy Align Technology (ALGN) Ahead of Earnings?

          Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

            Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up

            Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.

              What to Expect from International Paper (IP) in Q2 Earnings?

              Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.

                VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?

                Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.

                  PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1

                  PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.

                    Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?

                    Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.

                      Can Cerner (CERN) Deliver a Beat this Earnings Season?

                      We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.

                        What to Expect from Anthem (ANTM) this Earnings Season?

                        Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.

                          Centene (CNC) to Report Q2 Earnings: What's in the Cards?

                          Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.

                            Universal Health (UHS) Q2 Earnings: What's in the Cards?

                            Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.

                              Will Stryker (SYK) Deliver a Beat this Earnings Season?

                              The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.

                                Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up

                                Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.

                                  What's in Store for Express Scripts (ESRX) in Q2 Earnings?

                                  Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.

                                    Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?

                                    Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.

                                      Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas

                                      Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.

                                        Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?

                                        Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.

                                          GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?

                                          We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.

                                            Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?

                                            Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.

                                              Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?

                                              Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.

                                                Align Technology Hits a 52-Week High on Solid Prospects

                                                Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.

                                                  Medtronic InterStim System Shows Five-Year Positive Results

                                                  Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.